C12N 2770/18071
Demonstrated in vivo effect
C12N2770/18071 (Demonstrated in vivo effect) appears on 10 US grants and 21 published applications in this corpus.
Search patents in C12N- Granted patents
- 10
- Published applications
- 21
- Assignees
- 11
- Inventors
- 44
- Latest grant
- 6 May 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 2 | 8 |
| 2023 | 3 | 4 |
| 2024 | 4 | 4 |
| 2025 | 1 | 2 |
By publication year.
Recent patents
- Recombinant multivalent influenza viruses6 May 2025US 12,290,562 B2Wisconsin Alumni Research Foundation (WARF)
- Melt processed viral nanoparticle constructs3 Dec 2024US 12,156,947 B2Case Western Reserve University
- Coronavirus vaccine5 Nov 2024US 12,133,899 B2BioNTech SE
- RNA constructs and uses thereof9 Apr 2024US 11,951,185 B2BioNTech SE
- Coronavirus vaccine12 Mar 2024US 11,925,694 B2BioNTech SE
- Coronavirus vaccine31 Jul 2025US 2025/0242059 A1BioNTech SE
- Melt processed viral nanoparticle constructs19 Jun 2025US 2025/0195449 A1Case Western Reserve University
- Rna constructs and uses thereof28 Nov 2024US 2024/0390524 A1BioNTech SE
- Dendritic architectures as nonviral vectors in gene delivery27 Jun 2024US 2024/0207187 A1TIBA Biotech LLC
- Melt processed viral nanoparticle constructs21 Mar 2024US 2024/0091165 A1Case Western Reserve University
Most cited
By later US patents
- Mouse-adapted SARS-CoV-2 viruses and methods of use thereof12US 11,225,508 B1The University of North Carolina at Chapel Hill · 2022
- Coronavirus vaccine9US 11,547,673 B1BioNTech SE · 2023
- RNA constructs and uses thereof4US 11,779,659 B2BioNTech SE · 2023
- Recombinant multivalent influenza viruses2US 12,290,562 B2Wisconsin Alumni Research Foundation (WARF) · 2025
- Coronavirus vaccine1US 11,925,694 B2BioNTech SE · 2024